课题基金 / 基金详情

Enhancing Understanding of Harms and Benefits of Cardiac Monitoring During Breast Cancer Therapy

Enhancing Understanding of Harms and Benefits of Cardiac Monitoring During Breast Cancer Therapy
增强对乳腺癌治疗期间心脏监测的危害和益处的了解
批准号:
10224673
负责人:
Anthony Francis Yu
金额:
$17.72万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-08-01 至 2023-07-31
关键词:

项目摘要

项目成果

Anthony Francis Yu的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/文摘
英文摘要
PROJECT SUMMARY/ABSTRACT Dr. Yu, an adult cardiologist at Memorial Sloan Kettering (MSK) with advanced training in echocardiography, has demonstrated a strong commitment to developing a career as a clinical investigator in cardio-oncology. His long-term goal is to lead efforts to develop evidence-based strategies for the prevention, detection, and management of cancer therapy-associated cardiotoxicity in order to mitigate the competing cardiovascular causes of morbidity and mortality in cancer survivors. The career development and training plans outlined in this application have been tailored to provide Dr. Yu with the necessary skills, structured mentoring, and research experience to meet his long-term research and career goals and ensure a successful transition to independence as a clinician scientist. Members of a multidisciplinary mentorship team comprised of nationally recognized leaders in survivorship, cardio-oncology, and health outcomes are committed to providing close supervision and guidance to Dr. Yu in achieving all of the career development, training, and research objectives of this proposal. The overall objective of the scientific aspect of this proposal is to better understand the harms and benefits associated with cardiac monitoring during trastuzumab therapy. Cardiotoxicity is a well recognized adverse effect of trastuzumab therapy used to treat HER2-positive breast cancer. Clinical guidelines for cardiac monitoring during trastuzumab therapy recommend routine serial assessments of left ventricular ejection fraction (LVEF). However, evidence to support this one-size-fits-all recommendation for all patients treated with trastuzumab is lacking, particularly given the growing trend in the use of non-anthracycline trastuzumab-based regimens with safer cardiotoxicity risk profiles. There is also the potential harm that false- positive results or clinically insignificant LVEF declines detected during routine cardiac monitoring will unnecessarily lead to interruption or early termination of curative and life-saving breast cancer therapy and result in worse cancer outcomes. The central hypothesis is that a strategy of limited cardiac monitoring among women with a low cardiovascular risk profile and treated with a non-anthracycline trastuzumab-based regimen will be safe and less costly. Dr. Yu will address this central hypothesis using two distinct and complementary approaches. In Aim 1, he will capitalize on existing variations in the frequency of cardiac monitoring observed at MSK to retrospectively examine the association between adherence to cardiac monitoring guidelines and cardiotoxicity events. In Aim 2, acknowledging the limitations of a retrospective study design, he will prospectively evaluate the safety and feasibility of a limited cardiac monitoring strategy in patients treated with a non-anthracycline trastuzumab-based regimen. In Aim 3, he will estimate the healthcare utilization and costs associated with guideline-based versus limited cardiac monitoring strategies. The knowledge gained on the harms and benefits of cardiac monitoring will lay the groundwork to develop evidence-based recommendations for cardiac monitoring during breast cancer therapy.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
ARIC Welcomes Cancer Survivors Into Their Communities: Unraveling the Link Between Cancer and Cardiovascular Disease.
ARIC 欢迎癌症幸存者加入他们的社区:揭示癌症与心血管疾病之间的联系。
DOI: 10.1016/j.jacc.2022.04.041
发表时间: 2022
期刊: Journal of the American College of Cardiology
影响因子: 24
作者: [Yu,AnthonyF, Steingart,RichardM]
通讯作者: Steingart,RichardM
DOI: 10.1016/j.echo.2017.08.017
发表时间: 2018-01
期刊: Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
影响因子: --
作者: [Pun SC, Landau HJ, Riedel ER, Jordan J, Yu AF, Hassoun H, Chen CL, Steingart RM, Liu JE]
通讯作者: Liu JE
Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
基于非蒽环类曲妥珠单抗治疗 HER2 阳性乳腺癌的心脏安全性。
DOI: 10.1007/s10549-017-4362-x
发表时间: 2017
期刊: Breast cancer research and treatment
影响因子: 3.8
作者: [Yu,AnthonyF, Mukku,RoyB, Verma,Shivani, Liu,JenniferE, Oeffinger,KevinC, Steingart,RichardM, Hudis,CliffordA, Dang,ChauT]
通讯作者: Dang,ChauT
DOI: 10.1016/j.amjcard.2021.02.013
发表时间: 2021-05-15
期刊: The American journal of cardiology
影响因子: --
作者: [Al-Sadawi M, Hussain Y, Copeland-Halperin RS, Tobin JN, Moskowitz CS, Dang CT, Liu JE, Steingart RM, Johnson MN, Yu AF]
通讯作者: Yu AF
Intensive Blood Pressure Control During Cardiotoxic Breast Cancer Treatment (PROTECT) Trial
  • 批准号:
    10660289
  • 项目类别:
  • 资助金额:
    $63.42万
  • 财政年份:
    2023
  • 负责人:
    Anthony Francis Yu
  • 依托单位:
Effects of Exercise on Changes in Cardiovascular Biomarkers in Patients with Breast Cancer During Anthracycline-based Chemotherapy
  • 批准号:
    10579380
  • 项目类别:
  • 资助金额:
    $8.85万
  • 财政年份:
    2023
  • 负责人:
    Anthony Francis Yu
  • 依托单位:
Enhancing Understanding of Harms and Benefits of Cardiac Monitoring During Breast Cancer Therapy
  • 批准号:
    9979796
  • 项目类别:
  • 资助金额:
    $17.64万
  • 财政年份:
    2017
  • 负责人:
    Anthony Francis Yu
  • 依托单位:
海外基金